Antibodies against E-selectin
AssigneeCelltech Therapeutics Limited
InventorsRaymond John Owens, Martyn Kim Robinson
Life of this patent
Estimating the term…
Abstract
This invention relates to whole antibodies of neutral isotype having specificity for E-selectin, process for their preparation (using vectors), pharmaceutical compositions containing them, and their use in therapy and diagnosis. Said antibodies are variants of natural antibodies altered in the Fc region, especially in the CH2 domain, so that the interactions with antibodies Fc receptors and complement are very low.
Claims13
An antibody having specificity for E-selectin characterised in that the serine residue at position 228 of the hinge region has been altered to a proline residue.
A process for the production of an antibody having specificity for E-selectin characterised in that the serine residue at position 228 of the hinge region has been altered to a proline residue which process comprises:
- a) producing in an expression vector an operon having a DNA sequence which encodes an antibody heavy or light chain;
- b) producing in an expression vector an operon having a DNA sequence which encodes a complementary antibody heavy or light chain;
- c) transfecting a host cell with both operons;
- and
- d) culturing the transfected cell line to produce the antibody.
An antibody having a heavy chain comprising the sequence of SEQ ID NO:8.
An antibody having a light chain comprising the sequence of SEQ ID NO:10.
Dependencies are inferred from the claim text.